The present invention relates to a compound of formula I ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.7, m and n are as defined herein. These compounds are high potential NK-3 receptor antagonists useful for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).